Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Kelda M. Gardner"'
Autor:
Mary-Elizabeth M. Percival, Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Pamela S. Becker, Paul C. Hendrie, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey
Publikováno v:
Haematologica, Vol 106, Iss 8 (2020)
Few patients with cancer, including those with acute myeloid leukemia and high-grade myeloid neoplasms, participate in clinical trials. Broadening standard eligibility criteria may increase clinical trial participation. In this retrospective single-c
Externí odkaz:
https://doaj.org/article/0395b57df88646eda61744ee5d03ecfc
Autor:
Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Paul C. Hendrie, Mary-Elizabeth M. Percival, Pamela S. Becker, Heather A. Smith, Vivian G. Oehler, Johnnie J. Orozco, Ryan D. Cassaday, Kelda M. Gardner, Tara L. Chen, Sarah A. Buckley, Kaysey F. Orlowski, Asma Anwar, Elihu H. Estey, Roland B. Walter
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
Externí odkaz:
https://doaj.org/article/f4c60eaa187e447a9c5cf66831e4bbbf
Autor:
Roland B. Walter, Bruno C. Medeiros, Kelda M. Gardner, Kaysey F. Orlowski, Leonel Gallegos, Bart L. Scott, Paul C. Hendrie, Elihu H. Estey
Publikováno v:
Haematologica, Vol 99, Iss 1 (2014)
Epigenetic therapeutics such as the histone deacetylase inhibitor, vorinostat, and the DNA methyltransferase I inhibitor, azacitidine, enhance gemtuzumab ozogamicin efficacy in vitro. We therefore investigated vorinostat/azacitidine/gemtuzumab ozogam
Externí odkaz:
https://doaj.org/article/a48e037ac1f5450fa9441987e9993b83
Autor:
Roland B. Walter, Stephanie J. Lee, Kelda M. Gardner, Xiaoyu Chai, Kathleen Shannon-Dorcy, Frederick R. Appelbaum, Elihu H. Estey
Publikováno v:
Haematologica, Vol 96, Iss 6 (2011)
Due to infectious and bleeding risks, adults with acute myeloid leukemia or high-risk myelodysplastic syndromes typically remain hospitalized after remission induction chemotherapy until blood count recovery. Here, we explored the medical and financi
Externí odkaz:
https://doaj.org/article/6e0e8e9822cb4efbbceff824c31d9a34
Autor:
Piyanuch Kongtim, Mary-Elizabeth M. Percival, Timothy J Martins, Guangrong Qin, Niall Curley, Kelda M. Gardner, Sylvia Chien, Jin Dai, Vivian G. Oehler, C. Anthony Blau, Paul C. Hendrie, Ryan D. Cassaday, Anna B. Halpern, Bart L. Scott, Roland B. Walter, Heather Smith, Guido Marcucci, Pamela S. Becker
Publikováno v:
Blood. 140:1200-1202
Autor:
Noam E. Kopmar, Megan Othus, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Bart L. Scott, Paul C. Hendrie, Roland B. Walter, Pamela S. Becker, Elihu H. Estey, Mary-Elizabeth M. Percival
Publikováno v:
Leukemia. 36:1164-1166
Autor:
Kyle B. Woodward, Kimberly A. Foster, Soheil Meshinchi, Michael E. Coon, Elihu H. Estey, Tanya Cunningham, Tayla M Olsen, Kelda M. Gardner, Jamie Stokke, Melinda A. Biernacki, Robson G. Dossa, Marie Bleakley, Anthony Rongvaux, Michelle Brault, Carrie Cummings
Publikováno v:
J Clin Invest
The tight junction protein claudin-2 is upregulated in disease. Although many studies have linked intestinal barrier loss to local and systemic disease, these have relied on macromolecular probes. In vitro analyses show, however, that these probes ca
Autor:
Megan Othus, Elihu H. Estey, Mohamed L. Sorror, Anna B. Halpern, Sarah Mirahsani, Carole Shaw, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, Kelda M. Gardner, Roland B. Walter
Publikováno v:
Haematologica
Few patients with cancer, including those with acute myeloid leukemia and high-grade myeloid neoplasms, participate in clinical trials. Broadening standard eligibility criteria may increase clinical trial participation. In this retrospective single-c
Autor:
Pamela S. Becker, Mohamed L. Sorror, Mary-Elizabeth M. Percival, Hiba M Khan, Emily M Huebner, Sarah Mirahsani, Anna B. Halpern, Kelda M. Gardner, Roland B. Walter, Carole Shaw, Elihu H. Estey
Publikováno v:
Leukemia. 34:1169-1171
Autor:
Anna B. Halpern, Brenda M. Sandmaier, Mary-Elizabeth M. Percival, Paul C. Hendrie, Kelda M. Gardner, Roland B. Walter, Michael Hochman, Megan Othus, Carole Shaw, Elihu H. Estey
Publikováno v:
Leukemialymphoma. 62(6)
The presence of ‘measurable residual disease’ (MRD) is highly associated with relapse in patients achieving complete remission (CR) regardless of whether post-remission therapy includes allogeneic ...